Gyre Therapeutics, Inc.

23.63 USD
-0.58 (-2.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Gyre Therapeutics, Inc. stock is up 208.08% since 30 days ago. The next earnings date is Dec 21, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 17 November’s closed higher than October.

About Gyre Therapeutics, Inc.

Catalyst Biosciences, Inc. focuses on developing protease product candidates in the fields of hemostasis and complement regulation. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD) and CB 4332 for patients with deficiencies in complement factor I (CFI)